Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures.
Seventy-one mobilised PBSC collections were subject to CD34+ cell purification using the CEPRATE SC stem cell concentration system. The overall median purity of CD34+ cells was 69% (6-93%). CD34+ cell, and GM-CFC recoveries were 52% (8-107%) and 36% (3-118%). Purity was logarithmically related to the input percentage of CD34+ cells and starting requirements were established of 1% CD34 cell content for optimal purity and a minimum of 2 x 10(6)/kg CD34+ cells to ensure recovery of our minimum engraftment threshold of 1 x 10(6)/kg CD34+ cells. Reduction of the washing steps reduced non-specific cell losses and shortened the procedure but did not affect progenitor cell recovery. Purified CD34+ cells were reinfused following high-dose therapy in 35 patients. The median time to neutrophil recovery of 0.5 x 10(9)/l was 12 (10-23) days and to the attainment of platelet independence was 13 (7-100) days. The risks of delayed platelet recovery were related to the CD34+ cell dose infused and were identical to the risks when non-purified PBSC collections were used. In conclusion, purification of CD34+ cells using the CEPRATE device is reliable and the purified product results in prompt engraftment. The cell losses that occur do however restrict its use in many patients.
Watts
M J
MJ
University College London Medical School and University College London Hospitals, UK.
Sullivan
A M
AM
Ings
S J
SJ
Leverett
D
D
Peniket
A J
AJ
Perry
A R
AR
Williams
C D
CD
Devereux
S
S
Goldstone
A H
AH
Linch
D C
DC
D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis*; D001781:Blood Component Removal; D002469:Cell Separation / Q000379:methods*; D002846:Chromatography, Affinity / Q000379:methods*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000097:blood / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000473:pathology
D018952:Antigens, CD34